Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Pain Management

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1796066

Cover Image

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1796066

Acute Migraine Treatment

PUBLISHED:
PAGES: 374 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Acute Migraine Treatment Market to Reach US$9.4 Billion by 2030

The global market for Acute Migraine Treatment estimated at US$4.0 Billion in the year 2024, is expected to reach US$9.4 Billion by 2030, growing at a CAGR of 15.3% over the analysis period 2024-2030. Triptans Drug, one of the segments analyzed in the report, is expected to record a 17.2% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the CGRP Antagonist Drug segment is estimated at 13.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 20.5% CAGR

The Acute Migraine Treatment market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 20.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.1% and 13.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.

Global Acute Migraine Treatment Market - Key Trends & Drivers Summarized

How Is Acute Migraine Treatment Evolving to Address the Needs of a Growing Patient Population?

The treatment landscape for acute migraine is undergoing significant transformation as clinicians, researchers, and pharmaceutical companies strive to address the growing needs of patients who suffer from this debilitating neurological disorder. Acute migraine attacks, characterized by throbbing pain, nausea, photophobia, and phonophobia, can severely impair daily functioning and quality of life. Traditionally, treatments have relied heavily on non-specific pain relievers such as NSAIDs, and triptans, a class of serotonin receptor agonists that became the gold standard in the 1990s. While these drugs have provided relief for many, they are not effective or tolerable for all patients, especially those with cardiovascular comorbidities who cannot safely use vasoconstrictive medications. The emergence of newer classes of medications such as gepants (CGRP receptor antagonists) and ditans (serotonin 5-HT1F receptor agonists) represents a critical leap forward in targeting the underlying pathophysiology of migraines. These drugs offer efficacy without the cardiovascular risks associated with older treatments and can be used in a broader range of patients. In addition to oral medications, nasal sprays, injectables, and rapidly dissolving tablets are being introduced to offer faster relief and more convenient administration. This evolution in treatment modalities reflects a shift toward patient-centric care, emphasizing rapid onset, reduced side effects, and improved tolerability. As awareness of migraine’s impact on public health increases, both healthcare providers and patients are advocating for early and effective intervention, which is propelling research and innovation in the acute treatment space.

Why Are New Drug Classes Gaining Momentum in the Acute Migraine Treatment Market?

New drug classes are gaining momentum in the acute migraine treatment market because they offer mechanisms of action specifically designed to target the biochemical processes involved in migraine attacks. One of the most important breakthroughs in recent years has been the development of CGRP (calcitonin gene-related peptide) receptor antagonists, known as gepants. CGRP is a neuropeptide believed to play a pivotal role in migraine pathogenesis by promoting inflammation and vasodilation in cerebral blood vessels. Gepants such as ubrogepant and rimegepant have been approved in several countries and offer a non-vasoconstrictive option that is safe for individuals with cardiovascular risk factors. Similarly, ditans like lasmiditan work on serotonin 5-HT1F receptors to inhibit migraine-related pain signaling without causing blood vessel constriction, addressing an important gap left by triptans. These novel therapies are appealing to clinicians because they provide acute relief while avoiding the limitations associated with older treatments, including delayed onset of action, drug overuse headaches, and contraindications in vulnerable populations. Furthermore, advancements in drug delivery systems are improving bioavailability and patient adherence. Formulations such as intranasal sprays and oral dissolvable tablets allow for faster absorption and easier administration during an active migraine, when swallowing pills may be difficult. Clinical trials have also shown these newer treatments to be well tolerated, with fewer gastrointestinal side effects and lower risks of medication overuse. With regulatory approvals expanding and real-world data supporting their safety and efficacy, these new classes are reshaping how acute migraines are managed and prompting a reevaluation of treatment guidelines across the globe.

What Are the Key Considerations for Clinicians in Tailoring Acute Migraine Therapy to Individual Patients?

Clinicians managing acute migraine treatment must balance efficacy, tolerability, comorbidities, and patient preferences when tailoring therapy, making personalized care increasingly important in this space. One of the most critical considerations is the patient’s cardiovascular health, as traditional triptans are contraindicated in individuals with a history of stroke, heart disease, or uncontrolled hypertension due to their vasoconstrictive effects. For these patients, newer options like gepants and ditans offer safer alternatives. Another factor is the frequency and intensity of migraine attacks. Patients with infrequent attacks may respond well to NSAIDs or triptans, while those with more frequent or treatment-resistant migraines may require access to next-generation medications or combination therapies. Clinicians must also consider the timing of treatment initiation, as early intervention during the mild phase of a migraine is typically more effective than delayed treatment after pain has escalated. The mode of drug administration is another vital consideration. Some patients prefer oral tablets for convenience, while others may require non-oral options such as nasal sprays or injectables if nausea or vomiting accompanies their attacks. Side effect profiles, potential drug-drug interactions, and ease of use all factor into adherence and overall patient satisfaction. Additionally, understanding a patient's prior treatment history and any history of medication overuse headaches is essential to avoid compounding the condition. With the increasing availability of diverse treatment options, clinicians are now better equipped to design individualized strategies that optimize outcomes and enhance the patient experience. As shared decision-making becomes a standard of care, involving patients in choosing their treatment options is critical for long-term success in managing acute migraine attacks.

What Forces Are Driving Growth in the Global Acute Migraine Treatment Market?

The global growth of the acute migraine treatment market is being driven by a combination of epidemiological, technological, regulatory, and consumer-focused factors that are reshaping the approach to migraine care. First and foremost, the high prevalence of migraines worldwide, affecting an estimated one billion people, has established a vast and underserved patient base that continues to seek better and faster relief from symptoms. As awareness of migraine as a serious and disabling neurological condition grows, healthcare systems are investing more resources into diagnosis and treatment. The expansion of health insurance coverage in many countries and the increasing inclusion of migraine therapies in national formularies are also improving patient access to both traditional and innovative medications. On the technology front, pharmaceutical companies are leveraging advances in molecular biology and neuroscience to develop more precise drugs that target the specific pathways involved in migraine attacks, such as CGRP and serotonin subtypes. Regulatory agencies like the FDA and EMA are responding to the unmet needs of migraine patients by expediting approvals through mechanisms like fast-track and breakthrough designations. This has shortened development timelines and brought new therapies to market more quickly. Patient demand for treatments with fewer side effects, rapid onset of action, and broader safety profiles is influencing pharmaceutical R&D priorities and driving product differentiation. Moreover, the growth of digital health platforms and migraine tracking apps is enabling better data collection and disease management, fostering more personalized and responsive treatment approaches. Education efforts by patient advocacy groups and professional societies are also raising standards of care globally. Collectively, these forces are not only fueling the expansion of the acute migraine treatment market but also paving the way for a future where migraine care is more accessible, effective, and aligned with individual patient needs.

SCOPE OF STUDY:

The report analyzes the Acute Migraine Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug, Other Drug Types); Administration Route (Oral Administration, Injection Administration, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Agenus Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Biohaven Ltd.
  • CoLucid Pharmaceuticals Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • GlaxoSmithKline plc (GSK)
  • H. Lundbeck A/S
  • Impel Pharmaceuticals Inc.
  • Johnson & Johnson (Janssen)
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries
  • Tonix Pharmaceuticals
  • Zosano Pharma Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP38443

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Acute Migraine Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Migraine Throws the Spotlight on the Expanding Acute Migraine Treatment Market
    • Increased Awareness and Diagnosis Rates Propel Growth in Demand for Fast-Acting Therapeutic Options
    • Advancements in CGRP Receptor Antagonists and Ditans Drive Adoption of Targeted Non-Triptan Therapies
    • Shift Away from Opioid-Based Pain Management Strengthens Business Case for Safer, Migraine-Specific Medications
    • Here's the Story: Neurologists and Primary Care Providers Turning to New Drug Classes for Refractory Migraine Cases
    • Rise of Digital Health Tools and Telemedicine Accelerates Access to Acute Migraine Medications and Management Plans
    • Growing Use of Self-Injectable Devices and Orally Disintegrating Tablets Enhances Patient Compliance and Convenience
    • Expansion of Over-the-Counter (OTC) Options and Combination Formulations Spurs Consumer-Driven Market Growth
    • Pharmaceutical Innovation in Nasal Sprays and Inhalable Delivery Systems Sustains Focus on Rapid-Onset Relief
    • Chronic Migraine Sufferers Driving Dual Use of Preventive and Acute Therapies Boost Market Potential
    • Rising Demand for Non-Invasive Neuromodulation Devices Opens New Avenues for Acute Migraine Relief
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Acute Migraine Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Acute Migraine Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Acute Migraine Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Acute Migraine Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Triptans Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Triptans Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Triptans Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for CGRP Antagonist Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for CGRP Antagonist Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for CGRP Antagonist Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for NSAID Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for NSAID Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for NSAID Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Beta-Adrenergic Blockers Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Beta-Adrenergic Blockers Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Beta-Adrenergic Blockers Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ergot Alkaloids Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ergot Alkaloids Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Ergot Alkaloids Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Injection Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Injection Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Injection Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • JAPAN
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • CHINA
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • EUROPE
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Acute Migraine Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Acute Migraine Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • FRANCE
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • GERMANY
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Acute Migraine Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • INDIA
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Acute Migraine Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Acute Migraine Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Acute Migraine Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Acute Migraine Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • AFRICA
    • Acute Migraine Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Acute Migraine Treatment by Drug Type - Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Acute Migraine Treatment by Drug Type - Percentage Breakdown of Value Sales for Triptans Drug, CGRP Antagonist Drug, NSAID Drug, Beta-Adrenergic Blockers Drug, Ergot Alkaloids Drug and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Acute Migraine Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Acute Migraine Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Acute Migraine Treatment by Administration Route - Oral Administration, Injection Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Acute Migraine Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Other Administration Routes for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!